Status:
WITHDRAWN
Study Using Plasma for Patients Requiring Emergency Surgery
Lead Sponsor:
Ottawa Hospital Research Institute
Conditions:
Hemorrhagic Shock
Blood Coagulation Disorders
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Information on the management of casualties from the ongoing conflicts in Afghanistan and Iraq has brought in to question the traditional approach to blood transfusion in hemorrhaging patients. Presen...
Detailed Description
Investigations that have arisen from reviews of casualty management in the ongoing conflicts in Afghanistan and Iraq have challenged the standard approach to blood transfusion in hemorrhaging patients...
Eligibility Criteria
Inclusion
- Priority 1 life-saving surgery for hemorrhagic shock due to ruptured AAA or trauma
- Over 18 years of age
Exclusion
- They will not receive any blood products for religious reasons
- If surgery is not for hemorrhagic shock (e.g. subdural evacuation)
- Plasma already administered for documented coagulation deficit (e.g. coumadin, hemophilia)
- Allergy to plasma (e.g. IgA deficiency) or known allergy to Voluven® solution
- Shock that is solely due to non-hemorrhagic reasons
- Allergy to any vitamin
- Vital signs absent
Key Trial Info
Start Date :
March 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2013
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT01221389
Start Date
March 1 2012
End Date
March 1 2013
Last Update
May 8 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Ottawa Hospital
Ottawa, Ontario, Canada, K1Y4E9